practical (JO:) is expected to close in the coming days
SOMERSET, N.J. and COPENHAGEN, Denmark–(BUSINESS WIRE)– Catalent (NYSE: CTLT), a leader in enabling the development and delivery of better treatments for patients Worldwide, Novo Holdings A/S (Novo Holdings), a global life sciences investment firm, announced today that the two companies have satisfied all regulatory closing conditions for their pending transaction. The companies now expect to close the deal in the coming days.
Today represents an important step in our transition to private equity within Novo Holdings, a leading life sciences investment firm,” said Alessandro Maselli, President and CEO of Catalent. As we approach closing the transaction, I would like to thank the Catalent team for all of their hard work and share my excitement about the bright future of our company. With the support of Novo Holdings and access to additional resources, Catalent will be well positioned to drive innovation and enhance offerings to benefit the customers and patients they serve, ultimately accelerating our strategy to create value for stakeholders.
Jonathan Levy, Senior Partner at Novo Holdings, said: “We are pleased to have achieved this latest milestone, which we believe reflects the significant benefits that the proposed transaction is expected to bring. As we near completion, we are excited to partner with the Catalent team and support it in its mission to drive Innovation in the healthcare system and improving patient outcomes.
For additional information related to the transaction, please visit transaction.catalent.com.
Advisors
Citi and JP Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel to Catalent and Jones Day served as legal counsel to Catalent's Board of Directors. Morgan Stanley & Co. (NYSE:). LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP served as legal advisors to Novo Nordisk (NYSE:).
About Novo Holdings A/S
Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. Novo Holdings' purpose is to improve the health of people and the sustainability of society and the planet by generating attractive long-term returns on Novo Nordisk's enterprise assets.
Novo Holdings, wholly owned by the Novo Nordisk Foundation, is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes (OTC:) A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of stocks, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a global leader in life sciences investing. Through its Seed, Ventures, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of the end of 2023, Novo Holding's total assets amounted to €149 billion. www.novoholdings.dk
About Catalent Company
Catalent, Inc. (NYSE: CTLT) is a global leader in enabling pharmaceutical, biotechnology and consumer health partners to optimize product development, launch and full lifecycle delivery for patients around the world. With breadth and depth of expertise in development science, delivery technologies and multimodal manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions and blockbuster medicines. Catalent helps accelerate more than 1,500 partner development programs and launch more than 150 new products each year. Its flexible manufacturing platforms in more than 50 global locations deliver approximately 70 billion doses of approximately 8,000 products annually. Catalent's dedicated workforce is approximately 17,000 people and includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated revenue of approximately $4.4 billion in its fiscal year 2024. For more information, visit www.catalent.com.
Forward-looking statements
This press release and any related oral statements may include historical and forward-looking statements and guidance. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified by the use of statements that include expressions such as believe, expect, expect, intend, estimate, plan, project, anticipate, hope, expect, likely, may, could, target, will, will or other Words or phrases with similar meanings. Likewise, statements describing Catalent's goals, plans or objectives are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from Catalent's expectations, projections and guidance. Some factors that could cause actual results to differ materially from forward-looking statements include, but are not limited to, the pending merger of Catalent with a subsidiary of Novo Holdings (the Merger), the completion of the Merger on the expected terms and timing, including obtaining consents and approvals. other antitrust regulatory requirements, the satisfaction of other conditions to consummation of the merger, and potential merger-related litigation that could be brought by or against Catalent or Novo Holdings or each of them. subsidiaries, directors or officers, including the effects of any results related thereto, the risk that disruptions resulting from the merger will harm Catalent's relationships, and certain restrictions during the pendency of the merger that may affect Catalent's ability to pursue attractive business opportunities or strategic transactions.
These forward-looking statements speak only as of the date of this press release or as of the date on which they are made, and Catalent does not undertake and specifically disclaims any obligation to release publicly the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after These statements are dated or to reflect the occurrence of anticipated or unanticipated events.
View source version on Businesswire.com: https://www.businesswire.com/news/home/20241213700784/en/
Catalent
Investor:
Paul Surdes
+1 (732) 537-6325
investors@catalent.com
Media:
Laura Hurtas
+1(609) 240-7025
media@catalent.com
Novo Holdings
(Global Inquiries) Marie-Louise Gersen, Senior Communications Partner
(US INQUIRIES) Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk
Source: Catalent Company
